LDS/Medical Tests/22q11.2 Deletion/Duplication, FISH

22q11.2 Deletion/Duplication, FISH

22q11.2 Deletion/Duplication is a genetic condition where a small segment of genes at 22q11.2 is deleted or duplicated in chromosome 22. Clinical syndromes associated with 22q11.2 deletion include DiGeorge syndrome, CATCH22, and velocardiofacial syndrome. These syndromes are associated with congenital heart disease, recurrent infection due to immune dysfunction, cleft palate and other distinct facial features, cognitive delay and autoimmune disease. The general population risk of 22q11.2 deletion is about 1 in 4,000 live births and does not change with maternal age. Individuals with a 22q11.2 deletion have a 50% risk of having an affected offspring in each pregnancy. 22q11.2 duplication syndrome is less common than the 22q11.2 deletion. It is associated with developmental delay, intellectual disability and slow growth leading to short stature and weak muscle tone in affected individuals. About 70% of individuals with the duplication inherit it from one of their parents.

Identification of 22q deletions and duplications is typically based on FISH analysis of the 11.2 locus on chromosome 22. FISH is a highly sensitive molecular cytogenetic technique used to detect chromosome abnormalities that are difficult or impossible to visualize with traditional cytogenetics. It uses fluorescently labeled DNA probes that are hybridized to metaphase chromosome spreads or interphase nuclei. FISH validation studies have demonstrated greater than 99% analytical sensitivity for detecting deletions and duplications of the 22q11.2 region.

  • Aid in the diagnosis of 22q deletion/duplication syndromes
  • For detecting cryptic translocation involving 22q11.2 that are not demonstrated by conventional chromosome studies
  • Useful to identify pregnancies at increased risk for 22q11.2 deletion syndrome.

Negative:

  • Two fluorescent signals from control probe and target probe are visible. Therefore, any individual with a normal signal pattern in each metaphase is considered negative for this probe.

Positive:

  • Any patient with a FISH signal pattern indicating loss of the critical region (1 signal) will be reported as having a deletion of the region tested by this probe. This is consistent with a diagnosis of 22q deletion syndrome.
  • Any patient with a FISH signal pattern indicating duplication of the critical region (3 signals) will be reported as having a duplication of the region tested by this probe. This is consistent with a diagnosis 22q duplication syndrome.
  • Abnormal results are usually reported as follow: “The result is abnormal. A deletion of HIRA was observed, which is consistent with a diagnosis of 22q11.2 deletion/duplication syndrome.

The result is within normal limits. No deletion or duplication of the 22q11.2 or 22q13 critical regions was observed

Fluorescence in Situ Hybridization (FISH).

Specimen: Blood, amniotic fluid, chorionic villi, fixed cell pellet, biopsy.

Stability (depends on specimen type)

Blood, amniotic fluid, chorionic villi. 

  • Ambient: 24 hours
  • Refrigerated: Not applicable
  • Transportation: Within 24 hours

Fixed cells and tissues are stable at room temperature for longer. 

Comparative genomic hybridization (CGH), multiplex ligation-dependent probe amplification (MLPA) analysis, array genomic hybridization (array GH) testing, Karyotyping, Restriction fragment length polymorphism (RFLP) analysis PCR, microarray.
2-7 days In some cases, additional time may be needed for additional confirmatory tests.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login